Compare ARDX & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | NKX |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 640.3M |
| IPO Year | 2014 | 2002 |
| Metric | ARDX | NKX |
|---|---|---|
| Price | $3.02 | $11.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $12.80 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 369.2K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.21 | N/A |
| Revenue Next Year | $28.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $10.30 |
| 52 Week High | $8.40 | $13.20 |
| Indicator | ARDX | NKX |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 58.78 |
| Support Level | N/A | $10.30 |
| Resistance Level | $3.35 | $11.30 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 25.32 | 84.44 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.